Theradiag Reports 20% Revenue Growth in Q3 2023
11 Ottobre 2023 - 5:45PM
Business Wire
- Sales up 11% to €9.9m on September 30, 2023:
- +13% growth in Theranostics, driven by strong export growth
and accelerating i-tracker sales
- +9% growth in In Vitro Diagnostics, driven by strong export
performance and strategic partnership with Quotient
- Cash position under control at €5.5 M on September 30,
2023
Regulatory News:
THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a
company specializing in in vitro diagnostics for autoimmune
diseases and Theranostics, today announced its third-quarter sales
and cash position to September 30, 2023, data currently being
audited.
Sales of €9.9m on September 30, 2023
In thousands of euros
Q3 2022
Q3 2023
Change
30/09/2022
30/09/2023
Change
Revenue
2,644
3,183
+ 20%
8,908
9,884
+ 11%
Of which Theranostics revenue
1,552
1,611
+ 4%
4,580
5,180
+ 13%
Of which IVD revenue
1,092
1,572
+ 44%
4,329
4,704
+ 9%
In Q3 2023, Theradiag posted sales of 3.2 million euros,
compared with 2.6 million euros in Q3 2022, representing solid
growth of +20%, driven mainly by the In Vitro Diagnostics (IVD)
business, which grew by +44%.
On September 30, 2023, Theradiag had sales of €9.9 million,
compared with €8.9 million on September 30, 2022, an increase of
+11%, thanks to consistent sales performance across Theradiag's two
business lines: +13% for Theranostics and +9% for IVD.
Theranostics sales rose by +13% to almost 5.2 million
euros on September 30, 2023, still driven by the sales momentum of
the i-Tracker® test range. This increase continues to be driven by
very good export performances (+ 41%) and solid growth in France
(+17%), offsetting the downturn in the US market.
IVD recorded an increase in sales of around 9%, reaching
over 4.7 million euros at the end of September 2023. Despite the
end of the contract with Asuragen and the drop in instrument sales,
the business proved resilient thanks to a 60% increase in export
performance and the strategic partnership established with
Quotient.
Cash and cash equivalents at the end of September 2023 remain
under control at over 5.5 million euros.
Highlights of the 3rd quarter 2023
On September 29, 2023, the Boards of Directors of BIOSYNEX SA
and THERADIAG SA unanimously approved the principle of a proposed
merger by absorption of THERADIAG by BIOSYNEX (the "Merger
Project").
The Merger Project will be submitted for approval to the
Extraordinary General Meetings of BIOSYNEX and THERADIAG
shareholders, which will be held on December 15, 2023.
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2022, the Company posted revenue of €12.2 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011021154/en/
Theradiag CEO Simon Davière
contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tél.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33
(0)1 44 71 94 94 arouille@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024
